Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab

Clin Lung Cancer. 2019 Sep;20(5):e560-e563. doi: 10.1016/j.cllc.2019.06.022. Epub 2019 Jun 26.

Authors

Hamza N Gokozan¹, Judah D Friedman², Alvin H Schmaier², Katharine A Downes¹, Lisa A Farah³, Hollie M Reeves⁴

Affiliations

¹ Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH.
² Division of Hematology and Oncology, Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH.
³ Clinical Oncology, University Hospitals Geauga Medical Center, Chardon, OH.
⁴ Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH. Electronic address: hollie.reeves@uhhospitals.org.

PMID: 31311716
DOI: 10.1016/j.cllc.2019.06.022

No abstract available

Keywords: Acquired hemophilia A; Bethesda assay; Immunotherapy; Nivolumab; PD-1.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Squamous Cell / complications
Carcinoma, Squamous Cell / drug therapy*
Drug-Related Side Effects and Adverse Reactions / drug therapy*
Factor VIII / therapeutic use
Hemophilia A / drug therapy*
Hemophilia A / etiology
Humans
Immunotherapy / adverse effects*
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Male
Neoplasm Metastasis
Nivolumab / adverse effects
Nivolumab / therapeutic use*
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Rituximab / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
Rituximab
Factor VIII

Supplementary concepts

Factor 8 deficiency, acquired